InvestorsHub on MSN

20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare

BioLabs, Inc. (NASDAQ:AIDX) announced it has signed an exclusive U.S. technology licensing and access agreement with ROKIT ...

What's going on with 20/20 Biolabs stock?

Shares of 20/20 Biolabs, Inc. AIDX are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare. 20/20 ...

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed TherapiesExpands OneTest for Longevity with Chronic Kidney ...
STAT

A race-free algorithm is merely the start for a safety net hospital confronting an onslaught of kidney disease

This is Part 6 of Embedded Bias, a series revealing how race-based clinical algorithms pervade medicine and why it's so difficult to change them. NEW YORK — One Brooklyn Health, a safety net hospital ...
BioWorld

Roche secures CE mark for kidney disease algorithm

Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk Inc. to stratify risk and assess the progressive decline in kidney ...
STAT

Removing race from kidney function algorithm helped more Black patients access transplants

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Several years ago, nephrologists attempted a first-of-its-kind effort ...
Philadelphia Tribune

Greater Philly health systems remove race from clinical algorithms that guide decisions in kidney, lung and pregnancy care

Thirteen health systems in Greater Philadelphia are working as a coalition to reevaluate what role race has played in tools and guidelines that doctors and nurses use to diagnose and treat patients.